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Objective: Persistent endoleak and endotension, complications after endovascular aortic repair, may be caused by an
unorganized thrombus inside the aneurysm. The experimental study was designed to evaluate the effectiveness of stent
grafts (S/Gs) with slow release of basic fibroblast growth factor (bFGF) for the organization.
Methods: The S/Gs were constructed of self-expanding Z stent covered with expanded polytetra fluoroethylene graft, and
coated with elastin to be able to bind and slowly release bFGF. Five elastin-coated S/Gs with bFGF (bFGF-S/Gs) and
without bFGF (C-S/Gs) were placed in the normal canine aorta respectively. The thoracic aortic aneurysm models were
surgically created with a jugular vein patch in 12 beagles. S/Gs with six holes, for creating endoleaks, were used in the
experiment of aneurysmal repair. The bFGF-S/Gs (n  6) and C-S/Gs (n  6) were implanted. The beagles were
sacrificed at two weeks after the endovascular procedure and examined histologically.
Results: The bFGF-S/Gs induced six times the intimal proliferation of the C-S/Gs in normal aorta. Twelve animals had
successfully created aneurysms, and had endoleaks just after the endovascular procedure. At two weeks after the
endovascular procedure, the percentage of fibrous area in the aneurysmal cavity treated with bFGF-S/G (35.7  4.3%)
was significantly greater than C-S/G (13.6  2.2%) (P < .01).
Conclusion: bFGF-S/Gs are effective for accelerating organization of the aneurysm cavity and developing neointima.
Further research on bFGF-S/Gs would clarify the association of endoleaks. ( J Vasc Surg 2008;48:1306-14.)
Clinical Relevance: Endovascular stent graft placements are widespread as a safe and less invasive procedure with
acceptable clinical results. However, a persistent endoleak, which is blood-flow leak in the excluded cavity, or
endotension, which is pressure overload in the excluded cavity, inhibits organization and causes re-expansion of the
aneurysm in some cases. The cause of this complication is thought to be unorganized thrombus occupying the
intra-aneurysmal cavity. In this study, we examined the efficiency of stent-grafts with basic fibroblast growth factor
delivery system in the canine thoracic aortic aneurysm model with endoleaks. We found that this method can accelerate
thrombus organization of the aneurysmal cavity excluded by endovascular stent-grafts in spite of endoleaks. According
to our basic results, stent-grafts with a drug delivery system may be applied to endovascular treatments of aneurysms and
may improve results of the endovascular treatments.A first successful endovascular stent graft (S/G) place-
ment for an abdominal aortic aneurysm repair was reported
by Parodi et al in 1991,1 and for a thoracic aortic aneurysm
by Dake et al in 1994.2 Endovascular S/Gs placements are
widespread as a safe and less invasive procedure with accept-
able clinical results.2-11
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1306In successful cases, the thrombus within the excluded
aneurysmal cavity is gradually organized, followed by
shrinkage of the aneurysm.However, a persistent endoleak,
which is blood-flow leak in the excluded cavity, or endo-
tension, which is pressure overload in the excluded cavity,
inhibits organization and causes re-expansion of the aneu-
rysm in some cases.12-18 The cause of this complication is
thought to be unorganized thrombus occupying the intra-
aneurysmal cavity.12,14,19
We thought that this problem might be resolved by
accelerating organization. Various cell growth factors play
an important role in a healing of tissue. We chose basic
fibroblast growth factor (bFGF) because bFGF is known to
promote increase of vascular endothelial cells, smooth-
muscle cells, and fibroblast cells, and to have action to
promote production of type I collagen.20-22 Moreover,
bFGF is already used as ulcer skin treatment agent. The
disadvantage of bFGF is very short life span in vivo, which
is less than several minutes.23
We created S/Gs coated with elastin-heparin that were
able to bind and release bFGF persistently. Moreover, we
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5 Kajimoto et al 1307demonstrated that S/Gs were released and the effect of
bFGF continued for more than three weeks.
The purpose of this article is to describe the feasibility
of bFGF slow-release S/Gs for aorta and aortic aneurysm.
MATERIAL AND METHODS
Study design
The effectiveness of S/Gs with slow release of bFGF
was evaluated compared with conventional S/Gs. Ten
S/Gs, five S/Gs each with and without bFGF release, were
inserted into the normal thoracic aorta of two beagles to
examine the influence on the vascular wall of bFGF.
Twelve S/Gs, six S/Gs each with and without bFGF
were inserted into 12 beagles with thoracic aorta aneurysms
to examine the organization of excluded aneurysms.
The beagles were sacrificed at two or four weeks after
endovascular procedure, and analyzed macroscopically and
microscopically.
Stent Graft
The S/G was constructed of self-expanding Gianturco
stainless steel Z stent (Cook Critical Care, Inc, Blooming-
ton, Ind) covered with expanded polytetra fluoroethylene
(e-PTFE) graft (Impra, Tempe, Ariz). The stent was con-
structed with two bodies and had six bends on each end. The
outer diameter of the e-PTFE was doubled with a balloon
catheter. The outer diameters of the S/G were selected to be
10% to 20% larger than those of both the proximal and distal
landing zones measured in preoperative aortography (AOG).
The graft material was attached to the stent with 5-0 polypro-
pylene sutures (Ethicon, Somerville, NJ).
S/G was coated as follows: S/G was impregnated with
10% soluble elastin and 0.5% heparin sodium salt to bind
the materials. In addition, the S/Gwas soaked in a solution
of 2 g/mL human recombinant bFGF (R&D Systems,
Inc., Minneapolis, Minn) and S/G with bFGF (bFGF-
S/G) was created. We examined the adaptability of elastin
to the grafts by scanning electron microscopy. The in-
terspaces of the PTFE were filled up by elastin.
bFGF-S/G can elute bFGF according to the resolution
of elastin from ePTFE. As fundamental experiment on
bFGF-S/Gs, S/Gs with 125I labeled bFGF (human re-
combinant [125I] Bolton-hunter labeled, Perkin Elmer,
Waltham, Mass) were subcutaneously implanted into the
backs of wistar rats. The remaining isotope level of S/Gs
was measured with a gamma counter (COBRA Auto
Gamma counter; Packard Instruments Co., Inc., Downers
Grove, Ill). At implantation three weeks later, the remain-
ing isotope level of S/Gs was 16.7%. That is to say, the
effect of bFGF continued for more than three weeks.
An elastin-heparin S/G without bFGF (C-S/G) was
used as a control. In the aneurysmal repair experiment, we
made a 2mm hole in six places of the S/G to create type III
endoleaks (Fig 1, A).Aneurysm model
We used 12 adult beagles (weight 10.2 to 12.4 kg) in
this study. All animals were cared for in accordance with the
guidelines approved by the Mie University Animal Experi-
ment and Care Committee. The dog was sedated with an
intramuscular injection of ketamine hydrochloricde (10
mg/kg of body weight) and atropine sulfate (0.08mg/kg).
The trachea was intubated and respiration maintained with
2 L/min of oxygen delivered via a respirator pump (SN-
480-3, Shinano, Tokyo, Japan) after induction with intra-
venous sodium thiopental. Anesthesia was followed by
intravenous pentobarbital and pancuronium. An aortic
patch was constructed with the left external jugular vein in
the left lateral position. The left external jugular vein was
mobilized. The 3 cm-length external jugular vein was har-
vested and longitudinally opened to create a elliptically
patulous vein patch. The patch size was 30  15 mm. The
descending thoracic aorta was mobilized by left-side thora-
cotomy in the seventh intercostal space. Two pairs of
intercostal arteries were ligated. After the animals received
heparin (100 UI/kg), points proximal and distal to the
aorta were clamped. A 3 cm longitudinal aortotomy was
created approximately 3 cm proximal to the diaphragm.
The vein patch was sewn with 6-0 polypropylene running
sutures to create an aneurysmal pouch (Fig 1, B). Intrave-
nous hydration with normal saline was maintained during
surgery and antibiotics were given at surgery and continued
for three days. Each animal had postoperative transesopha-
gus echography (TEE) and AOG.
Image analysis
All dogs were examined using the TEE (SSA-550A
Ultrasound system, Toshiba Medical Inc., Tokyo, Japan)
and AOG (Stenoscope, GE Yokogawa Medical System,
Tokyo, Japan) before and after the endovascular procedure,
and at sacrifice.
The dog was sedated with the same methods as at
aneurismal creation. AOG was performed by the following
method. The sheath was inserted into the femoral artery
using the Seldinger method. The dog was given an intra-
venous injection of heparin (50 UI/kg), and 12 ml of
contrast agent (Iopamiron 300, Nihon Schering, Osaka,
Japan) was injected at a rate of 6 ml/sec with a 5 Fr pigtail
catheter through the sheath.
Endovascular procedure
The infrarenal abdominal aorta was used as the access
route. The abdominal aorta was exposed through a midline
laparotomy and mobilized. Heparin (100 UI/kg) was
given. The S/G was inserted into the 18 Fr Teflon delivery
sheath (Keller-Timmermans; Cook, Bloomington, Ind)
and deployed by quickly withdrawing the outer sheath
using the pusher mandrel. This procedure was assisted with
fluoroscopy.
phic
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Twelve beagles were sacrificed with a lethal dose of
anesthesia at two weeks after the endovascular procedure.
Two beagles, one each of the bFGF-S/Gs and the C-S/Gs
for aneurysm repair were sacrificed at four weeks. The
thoracic aorta was dissected and washed with saline and
fixed in 4% formalin. Specimens were made after the metal-
lic stent was removed. The cross-section specimens in the
maximum transverse diameter were analyzed macroscopi-
cally and microscopically.
Histologic analysis
The specimens were embedded in paraffin and sec-
tioned at 4 m. The paraffin sections were stained with
hematoxylin and eosin (H&E), Masson’s trichrome (MT),
elastica-van Gieson (EVG), and Sirius Red. Immunohisto-
chemistry was performed using an antibody to anti-alpha-
smooth muscle actin (-SMA) (1A4; Sigma, St Louis, Mo)
at a dilution of 1:750. The immunoreaction was detected
with 3,3=diaminobenzidine.
To determine the amount of neointima formation,
EVG staining of a cross section was carried out in the
Fig 1. Canine aneurysm model with endoleaks. A, The
Descending aortic aneurysms are surgically created with a
S/G was inserted. Endoleaks are present in the angiograexperiments for the normal aorta. Intimal thickness wascompared in a width ratio of neointima in ePTFE. In the
MT stain, the ratio of fibrosis and organization area in the
excluded aneurysmal cavity was calculated by processing
with analysis software NIH image (version 1.61, Macin-
tosh) in each group. In the Sirius Red stain (Sigma, St
Louis, Mo), the ratio of collagen fiber area was calculated
with the same method.
Statistical analysis
Data are presented as the mean  SD. For statistical
analysis, the Mann-Whitney test for independent samples
was selected and performed using Statview for Windows
version 5.0 (SAS Institute Inc., Cary, NC). A P value of less
than .05 was considered significant.
RESULTS
The effectiveness of bFGF-S/Gs for normal thoracic
aorta
The AOG showed no migration of S/Gs in sacrifice as
compared with the deployed position, and the patency of
the S/Gs was maintained in all cases. Macroscopically, the
proximal side of the bFGF-S/Gs was completely covered
with a 2mm hole in six places for creating endoleaks. B,
lar vein patch.C,Angiography around the time when the
late phase.S/G
juguwith intima; however, the proximal side of the C-S/Gs was
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vascular wall firmly. On the other hand, the C-S/Gs were
attached loosely (Fig 2, A-a, and 2, A-b). Histologically,
hematoxylin and eosin stain showed the outgrowth of
intimal hyperplasia beyond the boundaries of the graft (Fig
2, A-c, and 2, A-d).
In cross-section specimens, the width ratio of neointima
in ePTFE was 0.345  0.076 (bFGF-S/G) and 0.054 
0.0075 (C-S/G). The proliferation of intima in bFGF-S/Gs
was significantly high (P  .01) and about six times the
proliferation ratio of C-S/Gs (Fig 2, A-e, 2, A-f, and 2, B).
There was no difference in media in each group.
The effectiveness of bFGF-S/Gs for thoracic aortic
aneurysm
The aortic aneurysm developed successfully in all 12
beagles. Mean patch aneurysm dimensions determined by
TEE were an average of 16.8 mm (range, 15.0 to 18.6
mm). The mean diameter of the normal canine thoracic
aorta measured was an average of 7.7mm (range, 7.2 to 8.5
mm). The S/G placement procedures were carried out
successfully at four weeks after aneurysmal creation. Type
III endoleaks were present in all cases on AOG just after the
endovascular procedure (Fig 1,C); however all were absent
at sacrifice.
Ten beagles, C-S/G group (n  5) and bFGF-S/G
group (n 5), were without complications and sacrificed at
two weeks after endvascular procedure. The percentage of
fibrous area in the aneurysmal cavity was 13.6  2.2 %
(C-S/G) and 35.7  4.3 % (bFGF-S/G) by MT stain (Fig
3, A and B). The fibrosis ratio in the bFGF-S/G group was
significantly higher than the C-S/G group (P  .01). In a
high power view, it can be taken that bFGF-S/G acceler-
ated fibrosis.
In the bFGF-S/G group, the production of mature
collagen fiber by Sirius Red stain was found after teo weeks
(Fig 4, A). Furthermore, SMA-positive cells, smooth
muscle cells or myofibroblast cells, were found in the
aneurysmal cavities of the bFGF-S/G group (Fig 4, B).
In the four week model of the bFGF-S/G group,
fibrosis extended to the whole aneurysmal cavity. On the
other hand, the aneurysmal cavity in the C-S/G group was
occupied by almost fresh thrombus and fibrin (Fig 3, C).
DISCUSSION
Some aneurismal models are reported by several meth-
ods and materials. On the studies of aneurysmal wall and
cavity or the studies of endovascular graft function, suitable
aortic aneurysm model should have vessel’s peculiarity
(elasticity and extensibility). Therefore, native vessel tissue
is better material. The creation of aortic aneurysm by the
balloon dilatation technique, the elastase infusion tech-
nique, and vein patch are suitable methods. On the other
hand, prosthetic material and the sheath of the rectus
abdominis muscle do not examine the change of intima
(hyperplasia) and media of aneurismal aortic wall.
Faries’s aneurismal model using elastase and collage-
nase is noninvasive technically and similar to clinical statepathologically.24 This aneurysm model is more suitable to
studies of endovascular graft function. However, drug in-
duced aneurysm models may differ from one case to an-
other on size and inflammatory degree.We could create the
approximate equivalent aortic aneurysms (maximum trans-
verse diameter: 15.0 to 18.6 mm) in using the jugular vein
patch of the same size (30  15 mm).
Endoleak and endotension are critically important
complications of S/G placement. The rate of endoleak
immediately after thoracic aortic aneurysm S/G repair has
been reported to be between 4% and 30%.3,5,6,9 Most
endoleaks can be corrected by additional S/G placement
and/or balloon dilatation during the procedure; however,
endoleaks possibly related to expansion of the neck aneu-
rysm or migration of the device can occur during follow
up.5 Recently, some cases have been reported in which
aneurysms continue to expand and even rupture by en-
doleaks and endotension.14,15,25
The treatment methods for endoleaks depend on the
location of the leak and its type. Variousmethods have been
reported such as glue,12 coils,15 and ligation of branches;
however, these methods have shown residual endoleak.14
Surgical conversion to standard repair is the last resort for
refractory endoleaks associated with expansion of the sac.
Thrombus organization by fibrosis stimulation in the
excluded aneurysmal cavity may be an ideal clinical strategy
for preventing endoleaks and endotension. During the
natural process of organizing blood clots, the recruitment
of fibroblasts into the clot can be one of the most crucial
steps. They transform to myofibroblasts, which produce
collagen fibers and generate contraction forces, resulting in
stable organized tissues and shrinkage of the aneurysm.26
From the aspect of cell proliferation for thrombus
organization, it is thought that growth factors may be
effective, and they therefore attracted our interest. Basic
FGF is one of themost important growth factors in vascular
lesion formation, and induces the migration and prolifera-
tion of endothelial cells, smooth muscle cells and fibro-
blasts.20-22 The biological half-life of bFGF is short and is
reported as less than five minutes.23 Basic FGF is also
known as heparin-binding growth factor, because of its
high affinity for heparin.27 In our studies, bFGF was en-
abled by local and persistent administration using heparin
as ligand material. At sacrifice, we histopathologically in-
spected lung, kidney, and hepatic tissue to examine how
bFGF affected other organs in this experiment. Those
histopathology findings were normal.
We used hydrophilic elastin that our group has trans-
formed hydrophobic elastin as the coating material for
bFGF slow release. Dacron and ePTFE are used widely as
vascular prosthetic material for aortic S/Gs. The stretch of
ePTFE fabric is well-qualified for sheath delivery proce-
dure. It is difficult to coat ePTFE, because ePTFE is not
hydrophobic. Van der Bas et al reported bFGF release S/Gs
covered with collagen-coated Dacron, however not com-
pletely collagen-coated ePTFE.21 We confirmed it with an
electron microscope that ePTFE can be completely coated
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is completely covered with intima (b), while the proximal side of the C-S/Gs is not covered (a). Histological
findings of hematoxylin and eosin stain, the intimal outgrowth beyond the boundaries of the graft are present in
the bFGF-S/G group (d), however are not present in the C-S/G group (c). Cross-section specimens of canine
aorta at two weeks after the endovascular procedure show intimal hyperplasia (asterisks) in the bFGF-S/Gs
compared with the C-S/Gs (e, C-S/Gs; f, bFGF-S/Gs). †e-PTFE graft. ‡aortic wall. B, The width ratio of
neointima in ePTFE in the cross-section specimens. Proliferation of intima in the bFGF-S/G group is significantly
higher. §P  .01.
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Volume 48, Number 5 Kajimoto et al 1311Fig 3. Evaluation of organization in the aneurysmal cavity. A, The cross-section specimens in the maximum
transverse diameter are analyzed macroscopically and microscopically at 2 weeks after S/G insertion. The majority
of the aneurysmal cavity in the C-S/G group is composed of red blood cells (a and c). The aneurysmal cavity in
the bFGF-S/G group is partly filled with organizing tissues with cells and collagen fibers (b and d). B, Average
percentages of organized areas in the aneurysmal cavity in each group at two weeks after S/G insertion.
Organization in the bFGF-S/G group is more progressed than in the C-S/G group. C, Cross-section specimens
at four weeks after S/G insertion. The aneurysmal cavity in the bFGF-S/G group is almost completely filled with
cellular components (b). In the C-S/G group, the aneurysmal cavity is composed of many red blood cells and a
little fibrosis (a). A-a through d, C-a, and C-b, Masson’s trichrome stain; *P  .01; bars  100 m.
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limited availability in comparison with collagen.
It has been reported that the bFGF induce intimal
hyperplasia on aortic wall, however the effect of them on
aortic aneurysm is unknown.21 In our studies, the bFGF-
S/G promoted the production of collagenous fiber in
excluded aneurysmal cavity after two weeks. Pitton et al and
Formichi et al described that the organization of tissue in
aneurysms takes at least several months, and collagenous
fiber is partially accepted after four to six weeks.28,29 Our
study results may suggest that bFGF-S/G clearly promoted
Fig 4. Histological findings of Sirius red (A) and -SM
insertion. A, Collagen fiber stained with red is present in
in the C-S/G group (a). B, -SMA-positive cells stained
-SMA-positive cells are not present in the C-S/G grou
graft; bars  100m.the organization of tissue in aneurysms.In addition, -SMA-positive cells were immunohisto-
logically accepted in the excluded aneurysmal sac, particu-
larly in the bFGF-S/G group. It is thought that these cells
were smooth muscle cells or myofibroblast cells; therefore,
they may play an important role in the shrinking mecha-
nism of the aneurysmal sac. From this viewpoint, it may be
said that remodeling of the aneurysmal sac progresses.
Unfortunately we were not able to measure aneurysmal size
in sacrifice by TEE precisely because of an artifact.
Neointima formation and the intimal outgrowth be-
yond the boundaries of the graft were accelerated by the
in (B) in the aneurysmal cavity at two weeks after S/G
FGF-S/G group (b), while collagen fiber is not present
brown are present in the bFGF-S/G group (b), while
#1: aneurysmal wall; #2: aneurysmal cavity; #3: ePTFEA sta
the b
with
p (a).bFGF-S/Gs. It may be indicative of an improved seal/
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5 Kajimoto et al 1313fixation and, if so, may be related to prevent the migration
of S/G and type I endoleaks. Accelerated organization of
the excluded aneurysmal cavity by bFGF release S/G also
seems to prevent type II endoleaks and contribute to
shrinkage.
Endoleaks in our study could not be detected by AOG
in sacrifice. However, there is experimental evidence that
low-flow endoleaks cannot be reliably identified by conven-
tional imaging and can maintain intra-aneurysmal sac pres-
sure.13 It is thought that delayed computed tomographic
scan (delay time is 15 to 20 seconds) is the most useful to
recognize endoleaks at present.14 The radiological absence
of endoleak cannot be assumed to indicate the absence of
endotension. Engellau et al30 discovered that thrombo-
genic change in the excluded aneurysmal cavity resulted in
decreasing signal intensities in T2-weighted images.
There are several limitations of this study. First, the
aneurysmal wall used in our study had no atherosclerosis
and the influence on the vessel wall by bFGF may be
somewhat different. Second, our established model has
type III endoleaks, and does not have a persistent endoleak.
We followed up the endoleaks by angiography in some
beagles. Although the endoleaks were present after 24
hours of surgery, and then they were not detected after the
seventh day in any of the groups (data not presented). We
could not review the effects on the endoleaks by bFGF. To
ligate the intercostal arteries is due to the absence of out-
flow for endoleaks. Consequently, endoleaks seemed to be
dissolved in all cases. We would like to consider further
work with an established model of type II endoleak as well.
CONCLUSION
The bFGF-S/Gs accelerated neointima formation and
organization of the aneurysmal cavities. Further research
on bFGF-S/Gs would clarify the association of endoleaks.
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